ReviewFrontiers in oncology2020
The Role of HLA-G in Tumor Escape: Manipulating the Phenotype and Function of Immune Cells.
Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 49 citations in OpenAlex.
- Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.Nature medicine · 2022Trial
- Article
- Minimal immune response after transplantation of a cryopreserved human amniotic membrane on the ocular surface.Materials today. Bio · 2026Article
- Human Leukocyte Antigen (HLA) and Tumor Immunity: A Critical Link in Cancer Immunotherapy.Immunity, inflammation and disease · 2026Review
- The non-classical immune checkpoint HLA-G: a regulatory master switch governing tolerance, evasion, and translational frontiers.Frontiers in oncology · 2026Review
- Integrated plasma proteomics identifies HLA-G and osteopontin as circulating biomarkers of resistance to PD-1 inhibitor plus chemotherapy in choriocarcinoma.Frontiers in immunology · 2026Article
- Immune evasion strategies in AFP-producing gastric carcinoma: characterized by HLA-G expression and HLA class I deficiency.Virchows Archiv : an international journal of pathology · 2025Article
- Human leukocyte antigen-G in hepatocellular carcinoma driven by chronic viral hepatitis or steatotic liver disease.Scientific reports · 2025Article
- The role of HLA-G in primary biliary cholangitis and response to therapy.Frontiers in immunology · 2025Article
- A prognostic model for stomach adenocarcinoma based on hypoxia- and immune-related genes.Archives of medical science : AMS · 2025Article
- Uridine-cytidine kinase 2 is correlated with immune, DNA damage repair and promotion of cancer stemness in pan-cancer.Frontiers in oncology · 2025Article
- Cancer and Secretomes: HLA-G and Cancer Puzzle.Advances in experimental medicine and biology · 2025Review
- Targeting of Non-Classical Human Leukocyte Antigens as Novel Therapeutic Strategies in Cancer.Cancers · 2024Review
- The efficacy and applicability of chimeric antigen receptor (CAR) T cell-based regimens for primary bone tumors: A comprehensive review of current evidence.Journal of bone oncology · 2024Review
- Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy.Journal for immunotherapy of cancer · 2024Review
- Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context.Frontiers in immunology · 2024Review
- Clinical variables and genetic variants associated with perioperative anaphylaxis in Chinese Han population: A pilot study.The World Allergy Organization journal · 2024Article
- Immune cells and checkpoints in pancreatic adenocarcinoma: Association with clinical and pathological characteristics.PloS one · 2024Article
- IFN-γ in ovarian tumor microenvironment upregulates HLA-E expression and predicts a poor prognosis.Journal of ovarian research · 2023Article
- The Molecular Mechanisms of HLA-G Regulatory Function on Immune Cells during Early Pregnancy.Biomolecules · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human leukocyte antigen-G (HLA-G) is a non-classical major histocompatibility complex class I (MHC I) molecule, and under physiological conditions, its expression is strictly restricted to the maternal-fetal interface and immune-privileged organs where HLA-G is expected to contribute to establishment and maintenance of immune tolerance. However, the expression of HLA-G has been found in various types of tumors, and the level of its expression frequently correlates with high-grade histology and poor prognosis, raising the possibility that it may play a negative role in tumor immunity. ILT2 and ILT4, present on a broad of immune cells, have been identified as the main receptors engaging HLA-G, and their interactions have been found to allow the conversion of effectors like NK cells and T cells to anergic or unresponsive state, activated DCs to tolerogenic state, and to drive the differentiation of T cells toward suppressive phenotype. Therefore, tumors can employ HLA-G to modulate the phenotype and function of immune cells, allowing them to escape immune attack. In this review, we discuss the mechanism underlying HLA-G expression and function, its role played in each step of the tumor-immunity cycle, as well as the potential to target it for therapeutic benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.